{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T05:05:51Z","timestamp":1724735151340},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.mehy.2015.11.029","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T02:36:14Z","timestamp":1450319774000},"page":"71-75","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hypothesis: Fingolimod explores new horizons in treatment of lymphoma"],"prefix":"10.1016","volume":"86","author":[{"given":"Arsalan","family":"Azimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2015.11.029_b0005","unstructured":"SEER stat fact sheets\u2014Hodgkin lymphoma, Bethesda, MD. National Institutes of Health, U.S. Department of Health and Human Services. Available at: <http:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html>; 2008 [accessed 29.08.12]."},{"key":"10.1016\/j.mehy.2015.11.029_b0010","unstructured":"SEER stat fact sheets\u2014non-Hodgkin lymphoma, Bethesda, MD. National Institutes of Health, U.S. Department of Health and Human Services. Available at: <http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html>; 2008 [accessed 29.08.12]."},{"issue":"38","key":"10.1016\/j.mehy.2015.11.029_b0015","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.mehy.2015.11.029_b0020","unstructured":"American Cancer Society. Cancer facts & figures 2010. Available at: <http:\/\/www.cancer.org\/Research\/CancerFactsFigures\/CancerFactsFigures\/cancer-facts-and-figures-2010>; 2010 [accessed 16.02.11]."},{"key":"10.1016\/j.mehy.2015.11.029_b0025","unstructured":"The lymphoma guide information for patients and caregivers. Leukemia and Lymphoma Society; 2013 [retrieved 20.02.14]."},{"issue":"1","key":"10.1016\/j.mehy.2015.11.029_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1470-2045(03)01319-6","article-title":"Part I: Hodgkin\u2019s lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells","volume":"5","author":"Thomas","year":"2004","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.mehy.2015.11.029_b0035","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma","volume":"23","author":"Re","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mehy.2015.11.029_b0040","unstructured":"SEER stat fact sheets: non-Hodgkin lymphoma. NCI. [retrieved 18.02.14]."},{"key":"10.1016\/j.mehy.2015.11.029_b0045","unstructured":"What you need to know about Hodgkin lymphoma, Bethesda, MD. National Institutes of Health, U.S. Department of Health and Human Services. Available at: <http:\/\/cancer.gov\/cancertopics\/wyntk\/hodgkin>; 2008 [accessed 30.08.12]."},{"key":"10.1016\/j.mehy.2015.11.029_b0050","unstructured":"Adult non-Hodgkin lymphoma treatment: health professional version, Bethesda, MD. National Institutes of Health, U.S. Department of Health and Human Services. Available at: <www.cancer.gov\/cancertopics\/pdq\/treatment\/myeloma\/healthprofessional>; 2008 [accessed 30.08.12]."},{"key":"10.1016\/j.mehy.2015.11.029_b0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0041-1345(00)02126-6","article-title":"FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression","volume":"33","author":"Brinkmann","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.mehy.2015.11.029_b0060","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a way out: lymphocyte egress from lymphoid organs","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.mehy.2015.11.029_b0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.mehy.2015.11.029_b0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.biochem.73.011303.073731","article-title":"Lysophospholipid receptors: signaling and biology","volume":"73","author":"Ishii","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"5566","key":"10.1016\/j.mehy.2015.11.029_b0075","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mehy.2015.11.029_b0080","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2015.11.029_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","article-title":"Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis","volume":"75","author":"Mehling","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2015.11.029_b0090","first-page":"43","article-title":"Leukocyte circulation and migration into tissues","author":"Abbas","year":"2015"},{"key":"10.1016\/j.mehy.2015.11.029_b0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Daniel Pelletier","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2015.11.029_b0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors","volume":"18","author":"Graler","year":"2004","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.mehy.2015.11.029_b0105","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1016\/j.bmcl.2004.02.106","article-title":"Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720","volume":"14","author":"Hale","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.mehy.2015.11.029_b0110","unstructured":"Kathryn L, McCance RN, Sue E, Huether RN. Pathophysiology: the biologic basis for disease in adults and children. 7th ed. Unit VIII; [chapter 29], p. 1024\u20131029."},{"issue":"2","key":"10.1016\/j.mehy.2015.11.029_b0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2015.11.029_b0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1165\/ajrcmb.24.6.4323","article-title":"Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of Gi2-linked Rho kinase activity","volume":"24","author":"Liu","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.mehy.2015.11.029_b0125","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1074\/jbc.M009422200","article-title":"Sphingosine 1-phosphate induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho dependent activation of avh3- and h1-containing integrins","volume":"276","author":"Paik","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2015.11.029_b0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0092-8674(00)81661-X","article-title":"Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate","volume":"99","author":"Lee","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2015.11.029_b0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(01)00324-0","article-title":"Akt-mediated phosphorylation of the G protein coupled receptor EDG-1 is required for endothelial cell chemotaxis","volume":"8","author":"Lee","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.mehy.2015.11.029_b0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/0008-5472.CAN-05-2001","article-title":"Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization","volume":"66","author":"LaMontagne","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.mehy.2015.11.029_b0145","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1073\/pnas.1934494100","article-title":"VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors","volume":"100","author":"Igarashi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2015.11.029_b0150","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/156652412803833599","article-title":"Molecular targets of FTY720 (fingolimod)","volume":"12","author":"Pitman","year":"2012","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.mehy.2015.11.029_b0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007890-199601270-00006","article-title":"A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation","volume":"61","author":"Suzuki","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.mehy.2015.11.029_b0160","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-05-0021","article-title":"Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma","volume":"4","author":"Ho","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.mehy.2015.11.029_b0165","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1158\/1078-0432.CCR-05-0447","article-title":"FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.mehy.2015.11.029_b0170","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/sj.bjp.0705182","article-title":"A novel immunosuppressive agent FTY720 induced Aktdephosphorylation in leukemia cells","volume":"138","author":"Matsuoka","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2015.11.029_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.mehy.2015.11.029_b0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/mol.57.4.652","article-title":"Protein kinases as mediators of phosphoinositide 3-kinase signaling","volume":"57","author":"Toker","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1016\/j.mehy.2015.11.029_b0185","doi-asserted-by":"crossref","first-page":"e81907","DOI":"10.1371\/journal.pone.0081907","article-title":"Fingolimod (FTY720) stimulates Ca(2+)\/calcineurin signaling in fission yeast","volume":"8","author":"Hagihara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2015.11.029_b0190","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2006-03-011437","article-title":"The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors","volume":"109","author":"Payne","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2015.11.029_b0195","doi-asserted-by":"crossref","unstructured":"Yamashita M, Katsumata M, Iwashima M, Kimura M, Shimizu C, Kamata T, Shin T, Seki N, Suzuki S, Taniguchi M, Nakayama T. T cell receptor-induced calcineurin activation regulates T helper type 2 cell development by modifying the interleukin 4 receptor signaling complex. (June 2000).","DOI":"10.1084\/jem.191.11.1869"},{"issue":"7","key":"10.1016\/j.mehy.2015.11.029_b0200","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-010-0849-6","article-title":"Th17 cells: positive or negative role in tumor?","volume":"59","author":"Ji","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.mehy.2015.11.029_b0205","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","article-title":"Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.mehy.2015.11.029_b0210","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4049\/jimmunol.0902813","article-title":"Tumor microenvironments direct the recruitment and expansion of human Th17 cells","volume":"184","author":"Su","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2015.11.029_b0215","article-title":"Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response","author":"Alvarez","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.mehy.2015.11.029_b0220","first-page":"S234","article-title":"Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis","volume":"14","author":"Mehling","year":"2008","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2015.11.029_b0225","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0041-1345(00)02126-6","article-title":"FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression","volume":"33","author":"Brinkmann","year":"2001","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.mehy.2015.11.029_b0230","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2011-10-388892","article-title":"Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice","volume":"119","author":"Lorvik","year":"2012","journal-title":"Blood"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715004521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715004521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T16:14:28Z","timestamp":1567440868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987715004521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":46,"alternative-id":["S0306987715004521"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2015.11.029","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypothesis: Fingolimod explores new horizons in treatment of lymphoma","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2015.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}